Navigation Links
Lincare Holdings Inc. Reports Intention to File Shelf Registration Statement
Date:12/28/2007

CLEARWATER, Fla., Dec. 28 /PRNewswire-FirstCall/ -- Lincare Holdings Inc. (Nasdaq: LNCR) today announced that it intends to file with the U.S. Securities and Exchange Commission (the "SEC") a resale shelf registration statement on or before January 29, 2008 on Form S-3 pursuant to the terms of a registration rights agreement Lincare entered into on October 31, 2007 in connection with the sale of its $275 million principal amount of convertible senior debentures due 2037 - Series A and $275 million principal amount of convertible senior debentures due 2037 - Series B (collectively, the "Debentures") and the shares of Lincare common stock issuable upon conversion of the Debentures.

Public resales of the Debentures and the shares of Lincare common stock issuable upon conversion of the Debentures may not be made, nor may offers from the public to buy be accepted, prior to the time the shelf registration statement becomes effective.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of the Debentures, the shares of Lincare common stock issuable upon conversion of the Debentures or any other securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful.

Statements in this release concerning future events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All forward-looking statements, including the statements regarding Lincare's intention to file a shelf registration statement with the SEC, included in this document are subject to risks and uncertainties and are based upon information available to Lincare as of the date hereof. Lincare canno
'/>"/>

SOURCE Lincare Holdings Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Lincare Holdings Inc. Announces Third Quarter and First Nine Months 2007 Financial Results
2. Lincare Holdings Inc. Prices $500 Million Convertible Senior Debentures Offering
3. Zimmer Holdings Offer and ORTHOsoft Directors Circular Mailed to Shareholders
4. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
5. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
6. AHPC Holdings, Inc. Announces Intent to Deregister Common Stock With Securities and Exchange
7. Siemens Announces Early Termination of Hart-Scott-Rodino Waiting Period For Acquisition of Dade Behring Holdings, Inc.; U.S. Antitrust Clearance Achieved
8. Platinum Underwriters Holdings, Ltd. to Report Third Quarter 2007 Results on October 23, 2007
9. Air Methods Completes Acquisition of FSS Airholdings, Inc., Parent Company of CJ Systems Aviation Group, Inc.
10. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2007 Results
11. NightHawk Radiology Holdings, Inc. Announces Date for Third Quarter Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... ... Parents, educators and service providers of children living with autism will converge upon ... the growing demographic. , The National Autism Conference will be held Aug. ...
(Date:7/29/2015)... ... July 29, 2015 , ... The healthcare analytics ... user and region. Factors such as the rising pressure to curb healthcare costs, ... increase in venture capital investments are driving market growth. Check 149 data tables ...
(Date:7/29/2015)... ... July 29, 2015 , ... The ... a five-year period, expiring November 30, 2019, during its recent meeting. , The ... application demonstrating the program’s compliance with the NCCA’s Standards for the Accreditation of ...
(Date:7/29/2015)... ... July 29, 2015 , ... This year, the threat ... levels this spring. And, where there is water, mold is not far behind. Paul ... tips for protecting against water and mold damage. Paul Davis is regularly called on ...
(Date:7/29/2015)... Miami, FL (PRWEB) , ... July 29, 2015 , ... ... diagnosis patients suffering from drug or alcohol addiction and mental health disorders. Acu-detox may ... means of treating patients recovering from drug and alcohol addiction. Although acupuncture is not ...
Breaking Medicine News(10 mins):Health News:Penn State Conference to Address Instruction, Success for Children with Autism 2Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 2Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 3Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 4Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 5Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 2Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 3Health News:Paul Davis Offers Tips to Minimize Property Damage and Health Risks This Flood Season 2Health News:Paul Davis Offers Tips to Minimize Property Damage and Health Risks This Flood Season 3Health News:Miami Drug Rehab Introduces Acupuncture to Line of Holistic Healing for Addiction 2Health News:Miami Drug Rehab Introduces Acupuncture to Line of Holistic Healing for Addiction 3
... ReauthorizationWASHINGTON, Jan. 14 The following fact sheet was ... the House: Divided We Fail Partnership (AARP, Business Roundtable, ... "On behalf of Divided We Fail, we urge you ... Children,s Health Insurance Program (SCHIP). Our nation has a ...
... journal report:Study highlights:-- Cholesterol-lowering drug adherence drops with ... of going for 90 straight days without medication ... all co-payment group and twice as high in ... to the exempt group (received prescriptions without a ...
... Utilize MICROSPONGE(R) Delivery SystemCARLSBAD, Calif., Jan. 14 ... Micro Wash, the only prescription benzoyl ... delivery system, for the treatment of mild ... Wash contains 7% benzoyl peroxide.(Photo: http://www.newscom.com/cgi-bin/prnh/20090114/LA58962 ...
... Rehab MarketHOUSTON, Jan. 14 Anne Kieschnik, a complex ... joined Alliance Seating & Mobility (ASM), one ... Kieschnik is an Assistive Technology Professional (ATP) ... for ASM ( www.alliance-seating.com ) and is responsible for ...
... access journal reportStudy highlights:, , ... odds of having cardiovascular disease within 10 years may not be ... Most adults 50 years and younger have a low 10-year risk ... disease. , Researchers suggest using ...
... blood-sucking critters, resistance to insecticides increasing in urban areas , , ... insecticides appears to be why bed bugs are making a ... , Bed bugs in New York City, where infestations have ... mutations that weaken the effect of the pyrethroid toxins, such ...
Cached Medicine News:Health News:Health Care For 11 Million Children 2Health News:Health Care For 11 Million Children 3Health News:Health Care For 11 Million Children 4Health News:Co-Payment Increases Result in Gaps in Veterans' Prescription Usage 2Health News:Co-Payment Increases Result in Gaps in Veterans' Prescription Usage 3Health News:Co-Payment Increases Result in Gaps in Veterans' Prescription Usage 4Health News:SkinMedica(R) Launches NeoBenz(R) Micro Wash for Acne 2Health News:SkinMedica(R) Launches NeoBenz(R) Micro Wash for Acne 3Health News:Veteran Rehab Specialist, Anne Kieschnik, Joins Fast-Growing Alliance Seating & Mobility In Texas 2Health News:Veteran Rehab Specialist, Anne Kieschnik, Joins Fast-Growing Alliance Seating & Mobility In Texas 3Health News:Half of Adults 50 and Younger With Low 10-Year Risk of CVD Have High Lifetime Risk 2Health News:Half of Adults 50 and Younger With Low 10-Year Risk of CVD Have High Lifetime Risk 3Health News:Bed Bugs, Nearly Eradicated, Make a Comeback 2
(Date:7/29/2015)... Inc. (Vanda) (NASDAQ: VNDA ), today announced financial ... 30, 2015. "We are impressed with U.S. ... H. Polymeropoulos M.D., Vanda,s President and CEO, "further investments ... products set the stage for the next level of ... , Total net product sales for the second quarter ...
(Date:7/29/2015)... , July 29, 2015 Sangamo BioSciences, Inc. ... will release its second quarter 2015 financial results after ... press release will be followed by a conference call ... the public via telephone and webcast. During the conference ... and discuss other business matters. The conference ...
(Date:7/29/2015)... 2015 Immune Pharmaceuticals Inc. (NASDAQ: IMNP ) ... to $21.5 million through two financing agreements. The first, ... ("Hercules"), for a term loan of up to $9.5 ... Fund ("Discover"), for the sale to Discover of newly ... for up to $12 million in gross proceeds to ...
Breaking Medicine Technology:Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 2Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 3Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 4Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 5Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 6Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 7Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 8Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 9Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 10Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 11Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 12Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 13Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 14Sangamo BioSciences Announces Second Quarter 2015 Conference Call and Webcast 2Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors 2Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors 3Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors 4Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors 5Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors 6Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors 7
... Minocycline Showed Substantial,Reduction of Disease Activity in ... Treatment With Antibiotic Further Reduced Brain,Lesions and ... May 4, 2007 - New data from ... of Copaxone,(glatiramer acetate injection) along with the ...
... 2007 - Lux Biosciences,Inc., a privately held biotechnology ... today that the company's,next-generation calcineurin inhibitor, LX211, is ... Research in Vision and,Ophthalmology (ARVO) annual meeting, being ... an oral presentation being given on May 5 ...
Cached Medicine Technology:Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 6Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 7Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 8Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 9Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 10Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 11Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 12Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 2Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 3Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: